Stephen Sullivan Net Worth

Stephen Sullivan biography

Stephen J. Sullivan is Chairman of the Board of the Company. Mr. Sullivan served as Interim Chairman of the Board from January 1, 2016 to June 20, 2016. Mr. Sullivan joined Interpace as a director in September 2004 and has served as Chairman of various committees of the Board. Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees. In early 2010, Mr. Sullivan founded CRO Advisors LLC, a specialty consulting firm he continues to head. Previously, Mr. Sullivan was the president and chief executive officer and a member of the board of directors of Harlan Laboratories, Inc. (“Harlan”) (acquired by Huntingdon Life Sciences Inc.), a privately held global provider of preclinical research tools and services, from February 2006 through January 2010, when he retired from that position. Prior to joining Harlan in 2006, Mr. Sullivan was a senior vice president of Covance, Inc. (“Covance”) and the president of Covance Central Laboratories, Inc., a major division of Covance. Prior to joining Covance, Mr. Sullivan was chairman and chief executive officer of Xenometrix, Inc. (“Xenometrix”), a biotechnology company with proprietary gene expression technology. He assisted with the merger of Xenometrix with Discovery Partners International. Prior to Xenometrix, Mr. Sullivan was vice president and general manager of a global diagnostic sector of Abbott Laboratories.

How old is Stephen Sullivan?

Stephen Sullivan is 73, he's been the Chairman of the Board of Interpace Biosciences Inc since 2016. There are no older and 9 younger executives at Interpace Biosciences Inc.

What's Stephen Sullivan's mailing address?

Stephen's mailing address filed with the SEC is A, Morris Corporate Center 1, 300 Interpace Pkwy, Parsippany, NJ 07054, USA.

Insiders trading at Interpace Biosciences Inc

Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti и Graham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.

What does Interpace Biosciences Inc do?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Interpace Biosciences Inc executives and stock owners

Interpace Biosciences Inc executives and other stock owners filed with the SEC include:

• Jack Stover,
  President, Chief Executive Officer, Director
• Dr. Thomas W. Burnell Ph.D.,
  Pres, CEO & Director
• Fortunato Rocca,
  Independent Director
• Joseph Keegan,
  Independent Director
• Eric Lev,
  Non-Executive Director
• Robert Gorman,
  Director
• Edward Chan,
  Director
• Fred Knechtel,
  Chief Financial Officer, Treasurer, Secretary
• Stephen Sullivan,
  Chairman of the Board
• Patrick Kane,
  VP & Corp. Controller
• Dr. Alidad Mireskandari M.B.A., Ph.D.,
  Chief Devel. Officer
• Dr. Sydney D. Finkelstein,
  Chief Scientific Officer
• Thomas John Freeburg Ph.D.,
  CFO, Treasurer & Sec.
• Nat Krishnamurti,
  Interim CFO
• Graham G Miao,
  CFO
• William Jheartland Advisors...,
  
• Harry Glorikian,
  Director
• 2018 Limited Partnership Am...,
  10% owner
• Thomas W. Burnell,
  President & CEO
• Peter Kamin,
  10% owner
• Laurence Mc Carthy,
  Director
• Felice Schnoll Sussman,
  Director
• Gregory Richard,
  Chief Commerical Officer
• James Early,
  
• Vijay Aggarwal,
  Director
• Christopher Mc Carthy,
  Chief Financial Officer